Skip to main content

How medtech companies are navigating the spike in at-home testing

After the rollercoaster change in COVID-19 test demand, the question is what happens in 2022. With an unprecedented demand for rapid at-home coronavirus tests, medtechs are looking post-pandemic to sell over-the-counter and direct-to-consumer diagnostics for a myriad of other diseases beyond COVID-19.

included in this trendline
  • Thermo Fisher, Hologic ride wave of COVID-19 test demand, for now
  • Labcorp, PerkinElmer latest to target COVID-flu combo test market
  • Abbott, Quest, Quidel likely to benefit from Biden's COVID-19 testing push